Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management
Najeebah A. Bade(University of Maryland, Baltimore), Ashkan Emadi(University of Maryland, Baltimore), Maria R. Baer(University of Maryland, Baltimore), Alison Duffy, Justin Lawson, Ann B. Zimrin(University of Maryland, Baltimore), Jennie Y. Law(University of Maryland, Baltimore), Seung Tae Lee(University of Maryland, Baltimore), Edward A. Sausville(University of Maryland, Baltimore), Vu H. Duong(University of Maryland, Baltimore), Ciera Patzke, Crystal Lu(National Institutes of Health Clinical Center)
Cited by 42
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764